Cadisegliatin's CATT1 Phase 3 readout will determine whether a BTD-designated insulin adjunct can redefine T1D management

Bull

A positive readout would demonstrate statistically significant and clinically meaningful reductions in HbA1c and/or time-in-range versus placebo on top of insulin, validating cadisegliatin's GLP-1R/GCGR agonist mechanism in T1D without meaningful hypoglycemia amplification. Such a result would support an NDA submission leveraging the Breakthrough Therapy Designation for expedited review, and would position cadisegliatin as the first oral incretin-based insulin adjunct approved for T1D — a differentiated and potentially large commercial opportunity.

Bear

The most likely failure mode is insufficient HbA1c or time-in-range separation from placebo, particularly if residual beta-cell function heterogeneity in the enrolled population dilutes the treatment effect. A secondary concern is a safety signal involving hypoglycemia frequency or severity when combined with insulin, or gastrointestinal tolerability issues that could limit dose escalation and blunt efficacy — either of which would undermine the benefit-risk profile required for approval in a non-terminal indication.